CD Biosynsis offers high-efficiency CHO (Chinese Hamster Ovary) Cells Gene Knockout Services, providing permanent and precise deletion or disruption of target genes in this premier mammalian host. CHO cells are the industry workhorse for producing complex therapeutic proteins, monoclonal antibodies (mAbs), and biosimilars. Gene knockout is a foundational step in host cell engineering, utilized primarily to eliminate undesirable host functions, such as native proteases that degrade the product or genes involved in unfavorable glycosylation pathways. Leveraging the precision of CRISPR-Cas9 to induce double-strand breaks (DSBs), our services rely on the cell's Non-Homologous End Joining (NHEJ) pathway to generate stable, loss-of-function mutations (indels). We provide end-to-end solutions, from multiplex gRNA design to final clone screening, accelerating the development of superior CHO cell lines with enhanced viability, productivity, and product quality.
Get a QuoteGene knockout in CHO cells is often complex due to the host's pseudo-tetraploid genome, requiring disruption of multiple alleles. Our CRISPR-Cas9 platform is optimized to address this by focusing on high-efficiency, transient delivery of the editing machinery (RNP or optimized vector). Cas9 induces a double-strand break (DSB) at the target locus, which the cell typically repairs via the error-prone Non-Homologous End Joining (NHEJ) pathway. This repair often results in frameshift mutations (insertions or deletions, or indels) that functionally disrupt the gene. This strategy is critical for removing genes that negatively impact product stability (e.g., proteases) or cell viability (e.g., pro-apoptotic genes).
Allele Disruption Design
Design of gRNA(s) targeting the early coding sequence to maximize the chance of frame-shift mutations (indels) that disrupt all functional alleles in the pseudo-tetraploid CHO genome.
Multiplex Knockout (Multiplex gRNA)
Simultaneous introduction of multiple gRNAs to efficiently disrupt several genes (or multiple isoforms/alleles) in a single transformation step, accelerating chassis construction.
Indel Verification Primers
Design of robust PCR and sequencing primers spanning the gRNA cut site for definitive, clone-level verification of successful indel formation in all target alleles.
RNP Delivery System
Preference for Ribonucleoprotein (RNP) complexes (Cas9 protein + gRNA) for transient, high-efficiency, and low off-target delivery into CHO cells via electroporation.
Transient vs. Stable Cas9
Selection between transient Cas9 delivery (RNP/plasmid) for rapid editing or stable Cas9 expression (lentivirus) for sequential, complex multi-gene editing strategies.
Selection Marker Strategy
Use of co-transfected selection markers (e.g., Puromycin, G418) or metabolic selection (e.g., DHFR knockout followed by Methotrexate amplification) to enrich for edited clones.
Anti-Apoptosis Engineering
Knockout of pro-apoptotic genes (e.g., Bax, Bak, Caspases) to extend the viability phase of the cell culture, significantly increasing final product titer (Qp).
Glycosylation Pathway Control
Deletion of key native glycosylation enzymes (e.g., FUT8, GNAT) to eliminate undesirable glycan structures (e.g., fucose) and achieve desired glycoprofiles for mAbs.
Protease Gene Knockout
Disruption of host cell protease genes that degrade secreted recombinant proteins, ensuring the stability and integrity of the final biotherapeutic product.
A systematic process for achieving precise disruption and stable clone isolation.
1. Rational Design & RNP Preparation
2. Transfection & Selection
3. Single Cell Cloning & Screening
4. Clone Verification & Delivery
Identify target gene(s). Design and synthesize high-specificity gRNA(s) targeting the early coding region.
Prepare the Cas9 enzyme/gRNA Ribonucleoprotein (RNP) complex for transient delivery.
Design primers for verification of indel formation (TIDE/Sanger) at the target locus.
Deliver the RNP complex into the CHO host cell line via optimized electroporation/lipofection protocols.
Culture cells to allow the NHEJ repair pathway to finalize the genomic edit.
Apply antibiotic selection or FACS sorting to enrich for edited clones.
Genotype verification via TIDE/Sanger sequencing of the edited locus to confirm indel formation in all alleles.
Validate the final clone's functional stability (titer, viability) over multiple passages.
Delivery of the verified CHO master cell bank (MCB) and complete documentation.
Allele-Agnostic Disruption
Strategies are optimized to disrupt all functional alleles in the complex, pseudo-tetraploid CHO genome, ensuring complete loss of host function (e.g., full protease removal).
High Efficiency RNP Delivery
Preference for RNP delivery ensures transient Cas9 activity and low off-target editing, maximizing safety and editing speed in mammalian cells.
Enhanced Cell Line Fitness
Targeted knockout of pro-apoptotic genes and proteases directly translates into extended culture longevity and improved product stability and yield in bioreactors.
Rapid Clone Isolation
Integration of FACS and automated single-cell cloning accelerates the isolation and expansion of stable, high-performing knockout clones, shortening the development timeline.
1. How do you ensure knockout of all alleles in the CHO pseudo-tetraploid genome?
We use high-efficiency RNP delivery and select gRNAs that maximize indel formation in all alleles simultaneously. Final verification requires sequencing to confirm the presence of disruptive indels in every allele.
2. Why is NHEJ the preferred repair pathway for gene knockout?
NHEJ (Non-Homologous End Joining) is error-prone, meaning it usually introduces small insertions or deletions (indels) when repairing the Cas9 cut. These indels cause a frameshift, functionally disrupting the gene, which is the desired outcome for a knockout.
3. Can essential genes be targeted for knockout?
No, complete knockout of an essential gene is lethal. For essential genes, we recommend targeted gene knock-in to replace the native promoter with a weaker one, or using CRISPRi/Base Editing for non-lethal, tunable repression.
4. What is the advantage of knocking out pro-apoptotic genes?
Knocking out pro-apoptotic genes (those that signal cell death) extends the lifespan and viability of the CHO cells in the bioreactor, allowing the cells to continue producing the therapeutic protein for a longer period, increasing titer.
5. How is the knockout verified at the genomic level?
Verification is done through sequencing methods like TIDE analysis or Sanger sequencing of cloned PCR products, confirming that all target alleles contain the desired frameshift-inducing indel mutation.
6. Do you use antibiotic selection for every knockout project?
Selection markers are often co-transfected to enrich for edited cells. However, we also employ marker-free strategies and use FACS to screen for edited clones, eliminating the need for drug selection when possible.
7. What input is required to start a gene knockout project?
We require the specific CHO host cell line (e.g., CHO-K1, CHO-DG44, or a client-specific line) and the accession number or sequence of the target gene to be disrupted.
8. What is the difference between Gene Knockout and Gene Knock-in?
Knockout (KO) disrupts gene function using NHEJ, often for elimination. Knock-in (KI) inserts new DNA (e.g., a pathway) precisely at a specific site using the Homology-Directed Repair (HDR) pathway.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.